Mind-body program for patients with blood cancers
Mind-body Medicine as a Supportive Strategy for Patients With Malignant Hematological Diseases: a Randomized Controlled Trial
NA · Universität Duisburg-Essen · NCT03735992
This study tests whether a mind-body group program can help people with blood cancers who are in remission manage their fatigue and improve their overall well-being.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität Duisburg-Essen (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Stuttgart) |
| Trial ID | NCT03735992 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial investigates the effectiveness of a mind-body group program designed to manage fatigue in patients with malignant hematological diseases who are in complete remission after primary treatment. Participants will engage in a series of group sessions focusing on mind-body techniques to enhance their overall well-being. The study aims to provide supportive therapy that complements traditional medical treatments for these patients.
Who should consider this trial
Good fit: Ideal candidates are patients with malignant hematological diseases who are in complete remission and able to attend group sessions.
Not a fit: Patients currently undergoing chemotherapy, radiation, or other rehabilitation programs may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce fatigue and improve the quality of life for patients recovering from blood cancers.
How similar studies have performed: Other studies have shown promising results with mind-body interventions in cancer care, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation * Physical and mental ability to attent 8 of 11 group units Exclusion Criteria: * Chemotherapy, radiation, or rehabilitation programm during the study period * Pregnancy * Participation in other studies with behavioral interventions during the study period
Where this trial is running
Stuttgart
- Robert-Bosch-Krankenhaus, Abteilung für Hämatologie, Onkologie und Palliativmedizin — Stuttgart, Germany (RECRUITING)
Study contacts
- Study coordinator: Holger Cramer, PhD
- Email: holger.cramer@med.uni-tuebingen.de
- Phone: +4971181017860
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematologic Neoplasms, Supportive Therapy, Fatigue, Mind-body medicine, Complementary and alternative medicine